August 2012

US Health and Human Services Secretary Kathleen Sebelius has announced a national plan to fight Alzheimer’s disease that includes almost $8 million in funding for research related to an insulin nasal spray for the treatment… Read more . . .

Elevation Pharmaceuticals has announced that a Phase 2b study of its EP-101 glycopyrrolate inhalation solution in patients with moderate to severe COPD demonstrated that EP-101 produced statistically significant improvement in lung function compared to placebo… Read more . . .

Data from the Centers for Disease Control and Prevention (CDC) Asthma Call-back Survey show that 18.7 million US adults (8.2 percent) have asthma today out of approximately 29.1 million adults (12.7 percent) who have been… Read more . . .

Pulmatrix is presenting two posters at RDD, one titled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology,” and the other titled “Development of an iSPERSE Based Platform for the Delivery of… Read more . . .

Aptar Pharma is presenting results from a clinical study of patient ability to use its Prohaler DPI at RDD this week. The study, which was conducted by Professor Patrice Diot at the Centre Hospitalier Regional… Read more . . .

Liquidia Technologies has announced results from two studies of inhalation formulations created using the company’s PRINT (Particle Replication In Non-Wetting Templates) particle engineering technology. One study, published in the 2012 issue of the Journal of… Read more . . .

Pearl Therapeutics is presenting data from studies of its PT003 metered dose inhaler, glycopyrrolate (GP)/formoterol fumarate (FF) fixed dose combination for the treatment of moderate-to-severe COPD at a number of upcoming meetings. Pearl is also… Read more . . .